Novo Nordisk · 1 day ago
Internship - Microphysiological Systems (Liver Metabolism)
Watertown, MA
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company focused on life science innovation. The internship offers students the opportunity to work on developing and verifying novel cell culture conditions for microphysiological liver systems, contributing to the enhancement of metabolic modeling.
BiotechnologyHealthcarePharmaceuticalHealth CareMedical
No H1B
Responsibilities
Development and deployment of novel, complex, human-relevant in vitro models of both healthy and diseased organ function
Support in developing and verifying novel cell culture conditions to better mimic physiological states, focusing on parameters such as glucose, insulin, and fatty acid balance
Execution of biochemical assays for endpoints like albumin, CYP activity, insulin sensitivity, and lipid metabolism
Computational input from QSP modeling to guide prioritization of cell culture parameters
Qualification
Required
Must be a current student enrolled at an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
An in progress undergraduate degree in Biomedical Engineering or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
2026-02-09
Company data provided by crunchbase